McKesson Corporation vs PayPal Holdings, Inc. — how do they compare? McKesson Corporation trades at $930 (market cap $108.46B), while PayPal Holdings, Inc. trades at $55.05 (market cap $47.07B). The key difference: McKesson Corporation is far larger — about 2.3× PayPal Holdings, Inc.'s market cap, and PayPal Holdings, Inc. pays the higher dividend (1.02%). Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and PayPal Holdings, Inc. for 106 Days on average.
| MCK | PYPL | |
|---|---|---|
Market Cap | $108.46B | $47.07B |
Volume | 712,607 | 13,860,099 |
Sector | Health | Financials |
52-Week High | $995.69 | $75.75 |
52-Week Low | $725.17 | $39.08 |
Typical Hold Time | 74 Days | 106 Days |
Enterprise Value | $115.00B | $49.21B |
Dividend Yield | 0.4% | 1.02% |
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $910.33, down 1.23% today, but maintains strong analyst support with 80.65% buy ratings and a $956.43 consensus price target. The stock shows bullish technical momentum with recent earnings beats and a major distribution agreement extension with CVS Health through 2032. Revenue growth has accelerated from $264B in 2022 to $359B in 2025, though net margins remain thin at 1.12%.
MCK presents a compelling growth story with consistent earnings outperformance and strategic partnerships driving long-term visibility. However, investors face risks from margin compression, drug pricing pressures, and high leverage with negative shareholder equity. The current valuation at 24.42x P/E appears reasonable given the company's market leadership and oncology growth prospects.
PayPal (PYPL) trades at $54.95, up 0.62% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $56.47. The stock shows strong profitability with a net income margin of 14.36% and ROE of 24.5%, supported by recent earnings beats in Q1 and Q2 2026. A new partnership with Meta's AI agent for checkout services, announced on September 22, 2026, provides a potential growth catalyst amid competitive pressures in digital payments.
PYPL presents a value opportunity with a low P/E of 10.39 and solid cash flow, but faces risks from slowing branded checkout growth and intense fintech competition. The stock's upside hinges on successful execution of Venmo expansion and cost-cutting initiatives under new CEO Enrique Lores, with investor sentiment cautiously optimistic given the 35.71% buy rating from analysts.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →PayPal Holdings, Inc. operates as a technology platform company that enables digital and mobile payments on behalf of consumers and merchants. The Company offers online payment solutions. PayPal Holdings serves customers worldwide.
Read more on PYPL →